Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431936 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
A Phase 2 study of Hypertension and Blood Pressure, sponsored by Augusta University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02431936 is a Phase 2 study of Hypertension and Blood Pressure that has completed, run by Augusta University. The registered enrollment target is 50 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02431936, a Phase 2 study of Hypertension and Blood Pressure, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
High blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area. Previously the investigators showed that a significant number of AAs held onto or retained salt during mental stress (sodium retainers). The investigators believe that the increased salt load and resulting blood pressure load contributes to the eventual development of hypertension in these individuals. The purpose of this study is to find out if this response is due to the direct stimulation of the kidney (the organ that controls salt levels in the body, by the brain). To do this, the investigators will determine if a drug that stops the connection between the brain and the kidney during mental stress will prevent sodium retention in sodium retainers. Prazosin is an alpha adrenergic receptor blocker that has been approved by the Food and Drug Administration (FDA). None of the subjects who participate in this study have high blood pressure. The subjects will not know which testing week is the drug week and which is the placebo week.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431936
The ClinicalTrials.gov registry entry for NCT02431936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02431936 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02431936 about?
NCT02431936 is a clinical study titled "Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress". High blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area. Previously the investigators showed that a significant number of AAs held onto or retained salt during mental stress (sodium retainers). The investig...
What is the current status of trial NCT02431936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-04. Estimated completion is 2019-04-16.
What conditions does trial NCT02431936 study?
This clinical trial studies the following conditions: Hypertension, Blood Pressure, Stress, Psychological.
What interventions are being tested in trial NCT02431936?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT02431936?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02431936 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.